Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H21NO2.ClH |
| Molecular Weight | 331.836 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCN1CCC2=C3[C@H]1CC4=CC=C(O)C(O)=C4C3=CC=C2
InChI
InChIKey=PCOQOGIDTIFQAM-XFULWGLBSA-N
InChI=1S/C19H21NO2.ClH/c1-2-9-20-10-8-12-4-3-5-14-17(12)15(20)11-13-6-7-16(21)19(22)18(13)14;/h3-7,15,21-22H,2,8-11H2,1H3;1H/t15-;/m1./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H21NO2 |
| Molecular Weight | 295.3755 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Propylnorapomorphine is a potent and selective D2 receptor agonist. Propylnorapomorphine is used as a tool compound to label dopamine receptors in rodent brain, and elicits dopaminergic behavioural effects. It stimulates motor activity, induces stereotypic behaviour and sexual stimulation. Propylnorapomorphine was investigated in clinical trial against Parkinson's disease and schizophrenia
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 |
10.12 null [pKi] | ||
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24325578 |
8.74 null [pKi] | ||
Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) |
|||
Target ID: P35462 Gene ID: 1814.0 Gene Symbol: DRD3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12831994 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Synthesis and characterization of a novel series of agonist compounds as potential radiopharmaceuticals for imaging dopamine D₂/₃ receptors in their high-affinity state. | 2014-01-23 |
|
| Effects of unilateral 6-OHDA lesions on [3H]-N-propylnorapomorphine binding in striatum ex vivo and vulnerability to amphetamine-evoked dopamine release in rat. | 2011-02 |
|
| Kinetics of the uptake and distribution of the dopamine D(2,3) agonist (R)-N-[1-(11)C]n-propylnorapomorphine in brain of healthy and MPTP-treated Göttingen miniature pigs. | 2003-07 |
|
| Behavioral effects of (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally effective long-acting agent active at central dopamine receptors, and analogous aporphines. | 1982-10 |
|
| Potentiation of the aphrodisiac effect of N-n-propyl-norapomorphine by naloxone. | 1982-07-09 |
|
| 3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors. | 1979-07-01 |
|
| Aporphines. 15. Action of aporphine alkaloids on dopaminergic mechanisms in rat brain. | 1976-01 |
Patents
Sample Use Guides
In a clinical study against Parkinson's disease, propylnorapomorphine was administered orally. The most effect was observed at doses of 10 to 15 mg six time per day. In rodents, propylnorapomorphine is administered intraperitoneally.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24325578
Binding to dopamine D2 receptor was determined using [3H]spiperone as radioligand and HEK293 cells, expressing recombinant human D2. Dose-response curves were converted to Ki values. pKi for propylnorapomorphine is 10.12.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:57:35 GMT 2025
by
admin
on
Mon Mar 31 17:57:35 GMT 2025
|
| Record UNII |
86EPT6U9AT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
20382-71-2
Created by
admin on Mon Mar 31 17:57:35 GMT 2025 , Edited by admin on Mon Mar 31 17:57:35 GMT 2025
|
PRIMARY | |||
|
DTXSID601017969
Created by
admin on Mon Mar 31 17:57:35 GMT 2025 , Edited by admin on Mon Mar 31 17:57:35 GMT 2025
|
PRIMARY | |||
|
3032728
Created by
admin on Mon Mar 31 17:57:35 GMT 2025 , Edited by admin on Mon Mar 31 17:57:35 GMT 2025
|
PRIMARY | |||
|
86EPT6U9AT
Created by
admin on Mon Mar 31 17:57:35 GMT 2025 , Edited by admin on Mon Mar 31 17:57:35 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |